Targeted Modulation of the Gut Microbiota in Obesity: From Dietary Interventions to Bacteriophage-Based Precision Therapies
4 affiliations
- 1Facultad de Ciencias de la Nutrición y Gastronomía, Universidad Autónoma de Sinaloa, Culiacan 80019, Sinaloa, Mexico
- 2Laboratorio Nacional para la Investigación en Inocuidad Alimentaria (LANIIA), Centro de Investigación en Alimentación y Desarrollo, A.C. (CIAD), Culiacan 80110, Sinaloa, Mexico
- 3Centro de Inteligencia Artificial Aplicada e Innovación Tecnológica, Universidad Autónoma de Sinaloa, Culiacan 80019, Sinaloa, Mexico
- 4Centro de Investigación en Alimentación y Desarrollo, A.C. (CIAD), Unidad Mazatlán en Acuicultura y Manejo Ambiental, Mazatlan 82112, Sinaloa, Mexico
Abstract
Obesity is a complex chronic disease associated with metabolic and inflammatory alterations in which the gut microbiota has emerged as an important contributing factor. Obesity-associated gut dysbiosis involves not only changes in microbial composition but also alterations in microbial functions and metabolites that may affect intestinal barrier integrity, immune regulation, adipose tissue metabolism, insulin sensitivity, and glucose homeostasis. Current microbiota-modulating strategies, including dietary interventions, prebiotics, probiotics, synbiotics, and fecal microbiota transplantation, can influence the gut microbial ecosystem; however, their effects are often highly variable among individuals and generally lack the specificity required to selectively target disease-associated bacterial populations. These limitations have increased interest in precision microbiota modulation, which aims to selectively modify microbial populations, functions, or products while minimizing unnecessary alterations to the remaining microbial community. In this context, bacteriophages represent a promising biological tool because of their ability to specifically target bacterial hosts, offering the possibility of selectively reducing bacterial populations associated with obesity-related metabolic and inflammatory disturbances. Experimental studies and early human trials have shown that bacteriophage-based interventions can modulate gut microbial communities and influence inflammatory responses, supporting their potential relevance to obesity-associated chronic low-grade inflammation. However, no published clinical trials specifically evaluating targeted bacteriophage therapy for obesity treatment were identified, and its efficacy for obesity management remains unestablished. Further research is needed to identify and validate bacterial targets, optimize phage selection and cocktail design, and evaluate phage stability, bacterial resistance, immunomodulatory effects, safety, and host–microbiota interactions before clinical translation can be considered.
Related
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
- Gut microbiota, microbial metabolites, and mucosal barrier dysfunction in benign anorectal disorders and ulcerative colitis: shared mechanisms, clinical links, and precision interventions
- Nutritional Modulation of the Microbiota–Gut–Brain Axis in Cancer-Related Fatigue: A Narrative Review of Mechanisms, Biomarkers, and Interventions
- Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH
- Modeling microbiome modulation of tumor metabolic networks to predict synergistic therapies
BibTeX
@article{rodriguezarellano2026targeted,
title = {{Targeted Modulation of the Gut Microbiota in Obesity: From Dietary Interventions to Bacteriophage-Based Precision Therapies}},
author = {Sthefhany Nohemí Rodríguez-Arellano and Jean Pierre González-Gómez and José Roberto Aguirre-Sánchez and Bruno Gomez-Gil and Elisa Barrón-Cabrera and Cristobal Chaidez and Marcela de Jesús Vergara-Jiménez},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213508},
url = {https://www.mdpi.com/2072-6643/18/21/3508},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeted Modulation of the Gut Microbiota in Obesity: From Dietary Interventions to Bacteriophage-Based Precision Therapies
AU - Sthefhany Nohemí Rodríguez-Arellano
AU - Jean Pierre González-Gómez
AU - José Roberto Aguirre-Sánchez
AU - Bruno Gomez-Gil
AU - Elisa Barrón-Cabrera
AU - Cristobal Chaidez
AU - Marcela de Jesús Vergara-Jiménez
PY - 2026
DA - 2026/10/25
JO - Nutrients
DO - 10.3390/nu18213508
UR - https://www.mdpi.com/2072-6643/18/21/3508
AB - Obesity is a complex chronic disease associated with metabolic and inflammatory alterations in which the gut microbiota has emerged as an important contributing factor. Obesity-associated gut dysbiosis involves not only changes in microbial composition but also alterations in microbial functions and metabolites that may affect intestinal barrier integrity, immune regulation, adipose tissue metabolism, insulin sensitivity, and glucose homeostasis. Current microbiota-modulating strategies, including dietary interventions, prebiotics, probiotics, synbiotics, and fecal microbiota transplantation, can influence the gut microbial ecosystem; however, their effects are often highly variable among individuals and generally lack the specificity required to selectively target disease-associated bacterial populations. These limitations have increased interest in precision microbiota modulation, which aims to selectively modify microbial populations, functions, or products while minimizing unnecessary alterations to the remaining microbial community. In this context, bacteriophages represent a promising biological tool because of their ability to specifically target bacterial hosts, offering the possibility of selectively reducing bacterial populations associated with obesity-related metabolic and inflammatory disturbances. Experimental studies and early human trials have shown that bacteriophage-based interventions can modulate gut microbial communities and influence inflammatory responses, supporting their potential relevance to obesity-associated chronic low-grade inflammation. However, no published clinical trials specifically evaluating targeted bacteriophage therapy for obesity treatment were identified, and its efficacy for obesity management remains unestablished. Further research is needed to identify and validate bacterial targets, optimize phage selection and cocktail design, and evaluate phage stability, bacterial resistance, immunomodulatory effects, safety, and host–microbiota interactions before clinical translation can be considered.
SN - 2072-6643
ER -